Clinical Trials

Anatomic Stage III Breast Cancer AJCC v8

NCT04852887 2026-04-15

DEBRA

1,670 enrolled

Breast Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT05286437 2026-04-06

LaPemERLA

40 enrolled

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07492394 2026-04-02

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Breast Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Endometrial Neoplasms

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT03624244 2026-02-17

BFR-ESS

40 enrolled

Endometrial Stromal Tumors

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Endometrial Neoplasms

NCT06143631 2026-02-03

PLUM

Phase 4 Recruiting

140 enrolled

Leiomyoma

NCT06394804 2026-02-03

CHAMELEON

20 enrolled

Low-Grade Serous Ovarian Cancer

NCT05183828 2026-01-26

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Phase 4 Recruiting

68 enrolled

Carcinoma, Ductal

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

20 enrolled

Breast Neoplasms

NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

120 enrolled

HR Positive HER2 Negative Advanced Breast Cancer

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

102 enrolled

Breast Neoplasms

NCT06139107 2025-11-14

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 1 Recruiting

15 enrolled

Breast Neoplasms

NCT06041204 2025-09-03

Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism

Phase NA Recruiting

200 enrolled

Infertility, Female, Polycystic Ovary Syndrome

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting

80 enrolled

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2/3 Recruiting

29 enrolled

GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

32 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast Neoplasms

NCT06953882 2025-07-14

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

180 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT05464810 2025-05-23

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

40 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT03011684 2025-05-08

TALES

309 enrolled

Breast Neoplasms, Infertility

NCT05190094 2025-05-07

ICRG0201

80 enrolled

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

NCT05247268 2025-04-06

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

104 enrolled

Endometrial Neoplasms

NCT05872204 2025-03-19

ALEPRO

100 enrolled

Low Grade Serous Ovarian Carcinoma

NCT06813118 2025-02-06

Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case

Phase 1 Recruiting

42 enrolled

Polycystic Ovary Syndrome

NCT05601700 2025-01-27

LEPRE

132 enrolled

Carcinoma, Ovarian Epithelial

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT06235931 2024-02-01

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC

Phase NA Recruiting

34 enrolled

Breast Neoplasms

NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Phase NA Recruiting

HR Positive HER2 Negative Advanced Breast Cancer

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

236 enrolled

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

12 enrolled